Draft Community Rolling Action Plan (CoRAP) For 2025-2027 Unveiled

The European Chemicals Agency (ECHA) has published its draft update for the Community Rolling Action Plan (CoRAP) covering the years 2025 to 2027. This draft, released on 10 December 2024, includes 31 substances, 13 of which are newly added, and outlines a structured timeline for substance evaluations aimed at assessing potential risks to human health and the environment. The finalised CoRAP update is expected to be published in March 2025 after Member State consultations.

Key Highlights Of The CoRAP Draft 2025-2027

Substance Evaluations And Updates

The draft CoRAP proposes the evaluation of eight substances in 2025, with two groups of two substances each being assessed jointly. Fifteen substances are scheduled for 2026, and five for 2027. Among the substances currently listed in the 2024-2026 CoRAP, three are proposed for withdrawal due to lower priority or the sufficiency of existing data to address initial concerns.

Focus On New Substances

‍The draft identifies 13 new substances, flagged primarily due to concerns related to carcinogenicity, mutagenicity, reproductive toxicity (CMR), and persistent, bioaccumulative, and toxic properties (PBT). These substances also include potential endocrine disruptors and chemicals with high aggregate tonnage and worker exposure risks.

Stakeholder Engagement Encouraged

‍ECHA has urged registrants to update their dossiers with all relevant information by March 2025 to facilitate a thorough evaluation. Early communication between registrants and Member State authorities is recommended to address potential data gaps proactively.

Timeline And Next Steps

Member State Review

‍The draft CoRAP will be reviewed by Member State Competent Authorities and the ECHA Member State Committee, with their opinions expected by February 2025. This collaborative process ensures a scientifically robust evaluation framework.

Final Adoption

‍ECHA aims to finalise and adopt the CoRAP update on 25 March 2025. A justification document for each substance will be provided, offering transparency and detailed insights into the evaluation rationale.